Lipton RB, Brennan A, Palmer S, et al. Estimating the clinical effectiveness
Articles
June 19th 2018
Study Summary: Estimating the Value-Based Price Range of Erenumab for Migraine Prevention
Lipton RB, Brennan A, Palmer S, et al. Estimating the clinical effectiveness value-based price range of erenumab for the prevention of migraine in patients with prior treatment failures: a US societal perspective. [published online April 3, 2018]. J Med Econ. doi: 10.1080/13696998.2018.1457533.
This health economic analysis predicted that, compared with use of supportive care, erenumab treatment will reduce the direct and indirect costs associated with migraine and increase quality-adjusted life-years for patients who have previously experienced treatment failure with at least 1 preventive migraine treatment.
Latest Updated Articles
Published: November 15th 2024 | Updated: November 19th 2024
FDA Approves Revumenib for R/R Acute Leukemia With a KMT2A Translocation
Published: April 1st 2024 | Updated: November 5th 2024
What We're Reading: Concierge Nonprofit Hospitals; Kaiser Permanente Elderly Care Program; Health Care Not Among Top Voter Issues
Published: October 21st 2024 | Updated: October 24th 2024
Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions
Published: September 26th 2024 | Updated: October 1st 2024
Addressing Natural Disaster Takes Cooperation, Preparation to Ensure Patient Health
Published: May 9th 2024 | Updated: May 21st 2024
FDA Accepts Nivolumab Subcutaneous Injection Application, With Potential to Boost Access to PD-1 Inhibitors
Published: November 21st 2024 | Updated: November 22nd 2024
Polygenic Risk Scores Can Identify Patients Who Should Receive IOP-Lowering Treatment
